Resources for You
Rituxan (rituximab) Intravenous Injection
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2012
Warnings and Precautions
- Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).
- prolonged hypogammaglobulinemia
- infections with multiple types of pathogens.